Skip to main content

A novel start-loss mutation of the SLC29A3 gene in a consanguineous family with H syndrome: clinical characteristics, in silico analysis and literature review



The SLC29A3 gene, which encodes a nucleoside transporter protein, is primarily located in intracellular membranes. The mutations in this gene can give rise to various clinical manifestations, including H syndrome, dysosteosclerosis, Faisalabad histiocytosis, and pigmented hypertrichosis with insulin-dependent diabetes. The aim of this study is to present two Iranian patients with H syndrome and to describe a novel start-loss mutation in SLC29A3 gene.


In this study, we employed whole-exome sequencing (WES) as a method to identify genetic variations that contribute to the development of H syndrome in a 16-year-old girl and her 8-year-old brother. These siblings were part of an Iranian family with consanguineous parents. To confirmed the pathogenicity of the identified variant, we utilized in-silico tools and cross-referenced various databases to confirm its novelty. Additionally, we conducted a co-segregation study and verified the presence of the variant in the parents of the affected patients through Sanger sequencing.


In our study, we identified a novel start-loss mutation (c.2T > A, p.Met1Lys) in the SLC29A3 gene, which was found in both of two patients. Co-segregation analysis using Sanger sequencing confirmed that this variant was inherited from the parents. To evaluate the potential pathogenicity and novelty of this mutation, we consulted various databases. Additionally, we employed bioinformatics tools to predict the three-dimensional structure of the mutant SLC29A3 protein. These analyses were conducted with the aim of providing valuable insights into the functional implications of the identified mutation on the structure and function of the SLC29A3 protein.


Our study contributes to the expanding body of evidence supporting the association between mutations in the SLC29A3 gene and H syndrome. The molecular analysis of diseases related to SLC29A3 is crucial in understanding the range of variability and raising awareness of H syndrome, with the ultimate goal of facilitating early diagnosis and appropriate treatment. The discovery of this novel biallelic variant in the probands further underscores the significance of utilizing genetic testing approaches, such as WES, as dependable diagnostic tools for individuals with this particular condition.

Peer Review reports


H syndrome, also referred to as histiocytosis-lymphadenopathy plus syndrome or PHID, is an autosomal recessive disorder characterized by abnormal proliferation of histiocytes. This condition is caused by mutations in the SLC29A3 gene located on chromosome 10q22.1. The SLC29A3 gene encodes the human equilibrative nucleoside transporter (hENT3) protein [1]. ENT3 is a member of the SLC29-equilibrating nucleoside transporter family, a group of proteins involved in transporting nucleosides across cellular membranes. ENT3 is widely expressed in various tissues throughout the body. Its cellular expression is particularly significant in the membranes of lysosomes and mitochondria. These organelles play crucial roles in cellular metabolism and homeostasis, and the presence of ENT3 in their membranes suggests its involvement in nucleoside transport within these compartments [2].

ENT3 facilitates the passive, sodium-independent transport of nucleobases, nucleotides, and nucleotide analogs across the lysosomal membrane, allowing their movement from the lysosome to the cytoplasm. Similarly, it aids in the transport of these molecules across the inner mitochondrial membranes. These processes are essential for maintaining an adequate cytoplasmic pool of nucleosides necessary for various cellular pathways and functions [3, 4]. Mutations in SLC29A3 can lead to impaired phagocytosis, which in turn causes an excessive inflammatory response and abnormal proliferation of histiocytes, contributing to the clinical features observed in H syndrome [1, 5]. Furthermore, these mutations can hinder the transportation of nucleosides, resulting in the accumulation of nucleosides within the cells. This disruption in nucleoside transport can have significant impacts on cellular processes and contribute to the pathogenesis of H syndrome.

H syndrome can arise from various types of mutations in the SLC29A3 gene, including nonsense, missense, compound (involving multiple genetic alterations), or deletion mutations. The presence of different mutation types in SLC29A3 may partially explain the extensive variability observed between different families affected by H syndrome. The diverse array of genetic alterations in SLC29A3 can contribute to the wide range of clinical presentations and manifestations observed in individuals with H syndrome [6, 7].

H syndrome was initially described by Molho-Pessach et al. in 2008, and it was named as such because many of its clinical features start with the letter “H” [8]. The syndrome is characterized by several hallmark manifestations, including symmetrical hyperpigmentation of the skin accompanied by hypertrichosis and sclerodermatous induration, hyperglycemia or insulin-dependent diabetes mellitus, hearing loss, hypergonadotropic hypogonadism with scrotal masses, short stature, gynecomastia, hepatosplenomegaly, hallux valgus, and heart anomalies. It is currently recognized as a type of histiocytosis that affects multiple organs [9].

This study aims to elucidate the molecular basis of H syndrome in two affected individuals from a single Iranian family by employing WES methodology. WES specifically targets the sequencing of exons, which represent the crucial protein-coding regions of the genome. By examining the entire exome, the study aimed to identify any genetic variations or mutations that could be responsible for the development of H syndrome in the two patients.

Materials and methods


In this study, we conducted an examination of 2 patients, a 16-year-old girl and her 8-year-old brother, who was born to consanguineous parents. The both patients presented with fever, skin hyperpigmentation, hearing loss, organ enlargement, and diabetes. The documentation of this study conforms to the Declaration of Helsinki protocols, was approved by the Ethical Research Committee of the Golestan University of Medical Sciences (No. IR.GOUMS.REC.1401.227), and informed consent was given by the parents of the children for publication of photographs and a description of the children’s presentation.

DNA extraction

For genetic testing, whole blood samples were collected from patients, their normal sister and parents. Genomic DNA was extracted from blood samples by Yekta Tajhiz DNA extraction kit (Cat. No., FABGK001) according to the manufacturer’s instructions. DNA concentrations were calculated using a NanoDrop spectrophotometer.

Whole-exome sequencing

The DNA extracted from the sample was fragmented and tagged with barcodes, followed by a solution-based hybridization step using the Agilent SureSelect Human All Exon V7 Plus probe set. Subsequently, the exome sequence was obtained using next-generation sequencing on the Illumina NovaSeq 6000 platform. The sequencing process achieved an average target coverage of 100X, ensuring that 90–95% of bases had a minimum coverage of 20X.

Analysing WES data involved four steps: [1] The Burrows-Wheeler alignment software (version 0.7.5a) was employed to align cleaned reads to the human reference genome (hg19). [2] Duplicate reads were identified using Picard (version 2.25). [3] Realignment of insertions and deletions was conducted with the Genome Analysis Toolkit (GATK, version 2.4–9). [4] Variants were identified using both GATK and Samtools programs. The results were combined and annotated with various databases including dbSNP, the 1000 Genomes Project, and ClinVar. Annotation analysis of the detected variants was carried out using ANNOVAR software.

In-Silico analysis identified variant

To assess the potential disease-causing nature of the identified variant, we conducted an in-silico analysis. This analysis involved the utilization of computational tools, including ACMG [10], CADD [11], Mutation Taster [12], Polyphen-2 [13], SIFT [14], Panther [15], Fathmm [16], MUpro [17], and I-Mutant [18]. Additionally, we manually evaluated the most significant variations to confirm their correlation with actual clinical results.

Sequencing and Co-segregation study

The co-segregation analysis aimed to investigate the transmission of the identified genetic variation across generations. By evaluating the co-segregation of variants with the disease phenotype, we can determine their potential role in disease onset. During the initial stage, polymerase chain reaction (PCR) amplification was carried out by utilizing specialized primers designed to target the specific site of the identified variation within the SLC29A3 gene. Sanger sequencing was then conducted to validate and confirm the presence of the variation in the probands and their parents. Finally, the obtained sequence chromatograms were assessed using the Codon Code Aligner software.

Prediction of protein three-Dimensional structure

In our study, we employed the I-TASSER server ( to generate three-dimensional (3D) models of both the mutant and wild-type forms of SLC29A3. This server utilizes the Protein Data Bank (PDB) to identify similar sequences that correspond to different regions of the input sequence. These sequences are then combined to construct a comprehensive 3D structure, which is further refined using molecular simulations and modeling techniques to improve stability and optimize energy. To visualize the resulting model, we utilized the UCSF Chimera software (

Study of protein-protein interactions

To explore protein-protein interactions associated with SLC29A3, we employed the online tool STRING ( This resource incorporates information from various datasets, encompassing gene fusion, co-expression patterns, functional annotations, and experimental findings. It enables the prediction of potential protein partners that may interact with SLC29A3. Each identified interacting protein receives a comprehensive score between 0 and 1, reflecting the strength of the interaction. A score of 0 indicates limited interaction, whereas a score of 1 indicates substantial interaction.

Conservation analysis

To explore the evolutionary conservation of the amino acid sequence in the SLC29A3 protein, we employed the Clustal Omega web server. [19]. Our objective was to assess the protein sequence and determine its conservation across different species. We obtained SLC29A3 protein sequences from various species, such as the tropical clawed frog (Xenopus tropicalis), red junglefowl (Gallus gallus), house mouse (Mus musculus), brown rat (Rattus norvegicus), chimpanzee (Pan troglodytes), rhesus macaque (Macaca mulatta), humans (Homo sapiens), domestic cattle (Bos taurus), and dog (Canis lupus familiaris), from NCBI. These sequences were appropriately formatted for alignment using Clustal Omega.


Clinical finding

The studied families are of Iranian origin located in Golestan province (Northeast Iran). They were the offspring of healthy consanguineous parents. The pregnancy and delivery of these patients were uncomplicated and did not present any noteworthy issues. Importantly, there was no reported history of birth defects or spontaneous abortions within the family.

The patient 1 involves a 16-year-old girl. She exhibited symptoms of H syndrome from 9 year of age, including fever, widespread organ involvement, and additional manifestations affecting the skin, joints, hearing, and the endocrine system. Notably, she experienced bilateral hearing loss and exhibited cardiac, kidney dysfunction, and diabetes. Patient 2 was the younger brother (8-year-old) of patient 1. He exhibited symptoms of H syndrome at 6 year of age, including fever, lymphadenopathy, and organ enlargement, and skin hyperpigmentation, unilateral hearing loss, indicative of an auto inflammatory, endocrine, and cutaneous disorder, and diabetes. Figure 1 shows skin hyperpigmentation and hypertrichosis in both patients, which is more severe in patient 1. The clinical and demographic data are summarized in Table 1.

Fig. 1
figure 1

The clinical findings of two patients with H syndrome. (a and b) Proband 1, bilateral dark hyperpigmented with hypertrichosis on the front side of thighs and groin. (c) Proband 2, hyperpigmented, hypertrichotic skin lesions on the groin. It is crucial to note that H syndrome patients may present with a variety of symptoms and manifestations beyond those depicted in this figure

Table 1 Summary of clinical and demographic characteristics of children with H syndrome

Clinical genetic testing

WES was performed on both patients, considering their phenotypes and initial diagnosis. The genetic analysis led to the identification of a novel single nucleotide start loss variant in the SLC29A3 gene, specifically the c.2T > A (p.M1K) NM_018344.6 variant, which was found in both patients. This particular variant has been associated with the manifestation of H syndrome. Figure 2 illustrates the genomic position of the c.2T > A mutation within the SLC29A3 gene, providing details at both the chromosomal and nucleotide levels.

Fig. 2
figure 2

A graphical representation of the SLC29A3 gene structure and mutation position

Co-segregation study

To confirm the presence and inheritance pattern of the mutation, Sanger sequencing was conducted on the probands, their unaffected sibling, and their parents. The analysis revealed that the unaffected sibling and parents were carriers of the variant in a heterozygous state, while both patients were homozygous for the identified variant. Figure 3 displays the pedigree of the family affected by H syndrome, along with the sequencing chromatogram obtained from the WES data.

Fig. 3
figure 3

(a) Pedigree of family with H syndrome. Two children with H syndrome. The affected siblings are indicated with filled symbols. (b) Sanger sequencing chromatogram confirmation of WES showing a homozygous start loss Varian c.2T > A in the 16-yr old proband (marked with an arrow) and her 8-yr old brother. The mother, father and sister, who are healthy, are heterozygous for the mutation. (W/M: wild/mutant. M/M: mutant/mutant)

Pathogenicity and protein stability analysis

The identified variant, c.2T > A, is novel and has not been previously reported. In order to evaluate its potential pathogenicity and its effect on protein stability, we utilized multiple prediction tools. The results of this in silico analysis, conducted using various computational predictors including ACMG, Mutation Taster, CADD, Polyphen-2, SIFT, Panther, Fathmm, MUpro, and I-Mutant, are summarized in Table 2.

Table 2 Results of in silico analysis using computational predictors for the c.2T > A mutation in SLC29A3

Tertiary structure, and protein–protein Interaction

Figure 4a shows the 3D structure of the SLC29A3 protein, including both the wild-type form and the mutant form with the p.M1K variation. We used the String tool to find the interacting proteins of SLC29A3 that were closest in proximity. The first shell interactors of SLC29A3 are shown in Fig. 4b and include the following: SLC29A2, SLC29A1, SLC28A3, SLC28A2, SLC28A1, CD63, CLINT1, VTI1B, OSTM1, and SLC47A1. Among these proteins, it is predicted that SLC29A2, with a score of 0.925, has the highest level of interaction with SLC29A3. Second shell interactors are also present, including YKT6, VAMP4, VAMP8, STX5, STX6, STX7, and STX8.

Fig. 4
figure 4

(a) 3D structure of the SLC29A3 protein. (b) Prediction of protein-protein interaction based on STRING data, visualized by NetworkX. (c) Evolutionary conservation analysis of p.Met mutation on SLC29A3 using Clustal Omega tool

Amino acids conservation

The amino acid 1 (Methionine), which is the point of variation, was shown to be substantially conserved in all the investigated species when the SLC29A3 protein sequence was aligned across several species using the Clustal Omega tool. According to this finding, the residue is critical to the protein’s evolutionary and functional history. In Fig. 4c the outcomes are highlighted.


Molho-Pessach et al. first characterized H syndrome in a study of 10 patients from 6 consanguineous Arab families [20], who had hyperpigmentation, hypertrichosis, and indurated cutaneous patches in the middle and lower parts of their bodies. In addition, these patients experienced hepatosplenomegaly and sensorineural hearing loss [21]. The clinical observations of our patients were in agreement with the previously reported cases. Bolze et al. also observed that sensorineural hearing loss and hepatosplenomegaly are present in approximately half of the individuals diagnosed with H syndrome [22]. Numerous studies have consistently reported that hyperpigmentation and hypertrichosis are the most common clinical features observed in individuals with H syndrome, and they are often regarded as pathognomonic signs of the condition [7, 21]. However, Bloom et al. faced challenges in diagnosing their patients with H syndrome and were only able to achieve a diagnosis through WES. They attributed the diagnostic difficulties to the relatively recent description of the syndrome and the limited number of cases previously published [23].

Similarly, in Iran, there have been only a few reported cases of H syndrome, which can be attributed to the rarity of the syndrome and the overlapping clinical manifestations it shares with other conditions. As a result, diagnosing H syndrome in Iran and other regions with limited reported cases may be more challenging due to the lack of familiarity and awareness of the syndrome among healthcare professionals.

To date, more than 50 pathogenic or likely pathogenic variants with H syndrome have been reported (Table 3), predominantly from the Arab populations of Egypt, Iran, Tunisia, Israel, Turkey, Syria, and Morocco [24]. The majority of these patients are diagnosed in early life, typically due to the presence of either skin-related changes or diabetes mellitus. The average age at diagnosis is around 17 years [25]. According to the study conducted by El-Darouti et al., in a patient with a combination of hepatosplenomegaly, hearing loss, heart anomalies, hypertrichosis, hypogonadism, and short stature, H syndrome should be considered as a potential differential diagnosis [26].

Table 3 A summary of the mutations reported in SLC29A3 gene

The H syndrome is caused by the presence of mutations in both alleles of the SLC29A3 gene, which is located on chromosome 10q22 and encodes the hENT3 protein. This protein plays a vital role in transporting nucleosides across cellular membranes, thereby contributing to the regulation of the cytoplasmic pool of nucleosides necessary for nucleotide synthesis, including salvage pathways [4]. The histiocytes and macrophages rely on the salvage pathways for nucleotide synthesis since they have a deficiency in endogenous nucleotide production. The disruption of nucleoside reserves is believed to affect the intracellular synthesis rate of extracellular matrix proteins produced by histiocytes. This alteration ultimately leads to significant subcutaneous and dermal fibrosis, which is considered the primary pathological process in H syndrome [37].

As mentioned earlier, mutations in the SLC29A3 gene, including missense, nonsense, and deletion mutations, lead to various medical manifestations ranging from mild to severe, which are known as the same entity termed H syndrome. Currently, over 50 pathogenic or likely pathogenic mutations have been documented in the SLC29A3 gene [23, 32], but so far, no clear correlation between specific genotypes and phenotypes has been recognized [38]. Various allelic disorders have been identified, including pigmented hypertrichosis with insulin-dependent diabetes mellitus (PHID) syndrome, familial histiocytosis syndrome (FHS), Faisalabad histiocytosis (FHC), familial sinus histiocytosis with massive lymphadenopathy (FSHML; also named familial Rosai-Dorfman disease), and some types of dysosteosclerosis. However, due to the fact that H syndrome encompasses the majority of these clinical features and all of these disorders share identical mutations in the SLC29A3 gene, they are now considered to be the same entity [4, 21, 32, 39].

In this study, we identified a novel homozygous missense mutation in exon 2, c.2T > A p.(Met1Lys), on SLC29A3 (NM_018344.6) that results in H syndrome. To validate our findings, we performed Sanger sequencing, which not only confirmed the presence of the identified mutation but also demonstrated its co-segregation with the mutation in the parents. As the identified mutation in this study was a novel one, its potential pathogenicity was assessed using bioinformatics tools. These computational tools analyse various aspects of the mutation, such as its location within the gene, the predicted impact on protein structure and function, and its conservation across different species. Based on the results from these bioinformatics analyses, the pathogenicity of the mutation was evaluated. It is worth noting that variants at translational starts sites are disruptive as they prevent protein expression. These variants are often classified as pathogenic, unless an alternative translational start is shown to produce a functional isoform to rescue protein expression. the c.2T > A start codon mutation is expected to result in a complete loss of function of the SLC29A3-encoded ENT3 protein. This would likely have significant cellular and physiological consequences due to the important role of ENT3 in nucleoside transport. Further experimental validation would be needed to fully characterize the impact of this mutation. Ultimately, the findings from the bioinformatics assessment were confirmed, establishing the mutation as pathogenic and contributing to the development of the observed H syndrome. The defining characteristic of the syndrome is the presence of cutaneous hyperpigmentation and hypertrichosis, primarily observed on the lower limbs, typically manifesting in the first or second decade of life [35].

Patient 1 and Patient 2 both exhibited characteristic symptoms of the H syndrome, including hyperpigmented indurated plaques with hypertrichosis on their lower limbs. Additionally, both patients presented with short stature, insulin-dependent diabetes mellitus (IDDM), and elevated inflammatory markers. Patient 1 also experienced bilateral hearing loss, cardiac and kidney dysfunction, as well as diabetes, while Patient 2 had unilateral hearing loss, short stature, and diabetes. The clinical features of the older sister (Patient 1) were more pronounced and well-defined. The presented pedigree highlights the presence of phenotypic variability within affected individuals, suggesting that clinical features may continue to evolve over time. It is worth noting that the observed variation could be influenced by the age difference between the sister and her brother. It is important to note that our study had certain limitations. First, we did not conduct functional studies to evaluate the clinical features of mutant animal models with c.2T > A in SLC29A3 gene, which could provide more robust evidence for the pathogenicity of the identified mutation. Second, we did not evaluate the level of SLC29A3 protein expression using techniques such as western blot analysis, which could have been helpful in determining whether the mutation resulted in the production of truncated protein or complete loss of function. Furthermore, WES has limitations, as it cannot detect certain types of genetic variations, such as chromosomal structural rearrangements, copy number variations (CNVs), mosaicism, changes in repetitive DNA sequences, epigenetic modifications, alterations in mitochondrial genes, or variations in non-coding regions. To enhance our understanding of the precise role of the SLC29A3 gene in H syndrome, additional research and genetic investigations are crucial. These endeavors will contribute to a more comprehensive comprehension of the condition.


This research demonstrates that a specific genetic mutation, c.2T > A, which causes the loss of a start codon in a homozygous state, leads to a range of clinical symptoms associated with H syndrome. Alongside the presence of different variations of the gene, it appears that the diverse clinical manifestations strongly support the idea of the SLC29A3 gene having multiple effects and variable expression, possibly indicating the participation of other genes. In essence, these findings highlight the effectiveness of whole-exome sequencing as a valuable approach for identifying genes associated with genetic disorders in humans.

Data availability

The datasets generated and/or analyzed during the current study are available in the ClinVar repository, ClinVar accession number: SCV004697500.


  1. Molho-Pessach V, Lerer I, Abeliovich D, Agha Z, Libdeh AA, Broshtilova V, et al. The H syndrome is caused by mutations in the nucleoside transporter hENT3. Am J Hum Genet. 2008;83(4):529–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Fraitag S, Emile JF. Cutaneous histiocytoses in children. Histopathology. 2022;80(1):196–215.

    Article  PubMed  Google Scholar 

  3. Li R, Mak WW-S, Li J, Zheng C, Shiu PH-T, Seto S-W, et al. Structure-activity relationship studies of 4-((4-(2-fluorophenyl) piperazin-1-yl) methyl)-6-imino-N-(naphthalen-2-yl)-1, 3, 5-triazin-2-amine (FPMINT) Analogues as inhibitors of human equilibrative Nucleoside transporters. Front Pharmacol. 2022;13:837555.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kang N, Jun AH, Bhutia YD, Kannan N, Unadkat JD, Govindarajan R. Human equilibrative nucleoside transporter-3 (hENT3) spectrum disorder mutations impair nucleoside transport, protein localization, and stability. J Biol Chem. 2010;285(36):28343–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Govindarajan R, Leung GP, Zhou M, Tse C-M, Wang J, Unadkat JD. Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol. 2009;296(4):G910–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Al-Haggar M, Salem N, Wahba Y, Ahmad N, Jonard L, Abdel‐Hady D, et al. Novel homozygous SLC29A3 mutations among two unrelated Egyptian families with spectral features of H‐syndrome. Pediatr Diabetes. 2015;16(4):305–16.

    Article  CAS  PubMed  Google Scholar 

  7. Molho-Pessach V, Varma M, Godbole K, Kamath N, Zlotogorski A. H syndrome–four new patients from India. Indian J Dermatol Venereol Leprol. 2014;80(6):579.

    Article  PubMed  Google Scholar 

  8. Shankar SG, Rangarajan S, Priyadarshini A, Swaminathan A, Sundaram M. Homozygosity for a novel large deletion in SLC29A3 in a patient with H syndrome. Pediatr Dermatol. 2020;37(2):333–6.

    Article  PubMed  Google Scholar 

  9. Jacquot R, Jouret M, Valentin MG, Richard M, Jamilloux Y, Rousset F et al. H syndrome treated with Tocilizumab: two case reports and literature review. Front Immunol. 2023;14.

  10. Kopanos C, Tsiolkas V, Kouris A, Chapple CE, Aguilera MA, Meyer R, et al. VarSome: the human genomic variant search engine. Bioinformatics. 2019;35(11):1978–80.

    Article  CAS  PubMed  Google Scholar 

  11. Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2019;47(D1):D886–94.

    Article  CAS  PubMed  Google Scholar 

  12. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods. 2014;11(4):361–2.

    Article  CAS  PubMed  Google Scholar 

  13. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013;76(1):1–52.

    Google Scholar 

  14. Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31(13):3812–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Thomas PD, Ebert D, Muruganujan A, Mushayahama T, Albou LP, Mi H. PANTHER: making genome-scale phylogenetics accessible to all. Protein Sci. 2022;31(1):8–22.

    Article  CAS  PubMed  Google Scholar 

  16. Shihab HA, Gough J, Cooper DN, Stenson PD, Barker GL, Edwards KJ, et al. Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models. Hum Mutat. 2013;34(1):57–65.

    Article  CAS  PubMed  Google Scholar 

  17. Cheng J, Randall A, Baldi P. Prediction of protein stability changes for single-site mutations using support vector machines. Proteins. 2006;62(4):1125–32.

    Article  CAS  PubMed  Google Scholar 

  18. Capriotti E, Fariselli P, Casadio R. I-Mutant2. 0: predicting stability changes upon mutation from the protein sequence or structure. Nucleic Acids Res. 2005;33(suppl2):W306–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Sievers F, Higgins DG. Clustal Omega, accurate alignment of very large numbers of sequences. Methods Mol Biol. 2014;1079:105–16.

    Article  CAS  PubMed  Google Scholar 

  20. Hamsho S, Alaswad M, Sleiay M, Alhusseini A. Hyperglycemia with hypogonadism and growth hormone deficiency in a 17-year-old male with H syndrome: the first case report from Syria. BMC Endocr Disord. 2023;23(1):274.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Molho-Pessach V, Agha Z, Aamar S, Glaser B, Doviner V, Hiller N, et al. The H syndrome: a genodermatosis characterized by indurated, hyperpigmented, and hypertrichotic skin with systemic manifestations. J Am Acad Dermatol. 2008;59(1):79–85.

    Article  PubMed  Google Scholar 

  22. Bolze A, Abhyankar A, Grant AV, Patel B, Yadav R, Byun M, et al. A mild form of SLC29A3 disorder: a frameshift deletion leads to the paradoxical translation of an otherwise noncoding mRNA splice variant. PLoS ONE. 2012;7(1):e29708.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Bloom JL, Lin C, Imundo L, Guthery S, Stepenaskie S, Galambos C, et al. H syndrome: 5 new cases from the United States with novel features and responses to therapy. Pediatr Rheumatol Online J. 2017;15(1):76.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Chouk H, Ben Rejeb M, Boussofara L, Elmabrouk H, Ghariani N, Sriha B, et al. Phenotypic intrafamilial variability including H syndrome and Rosai–Dorfman disease associated with the same c. 1088G > A mutation in the SLC29A3 gene. Hum Genomics. 2021;15:1–10.

    Article  Google Scholar 

  25. Amalnath D, Lingala R, Subrahmanyam D. H syndrome presenting with sinus of Valsalva Aneurysm and possible founder mutation (p.Arg134cys) in Indian patients. Indian J Dermatology. 2023;68(3):344–6.

    Google Scholar 

  26. Doviner V, Maly A, Ne’eman Z, Qawasmi R, Aamar S, Sultan M, et al. H syndrome: recently defined genodermatosis with distinct histologic features. A morphological, histochemical, immunohistochemical, and ultrastructural study of 10 cases. Am J Dermatopathol. 2010;32(2):118–28.

    Article  PubMed  Google Scholar 

  27. Morgan NV, Morris MR, Cangul H, Gleeson D, Straatman-Iwanowska A, Davies N, et al. Mutations in SLC29A3, encoding an equilibrative nucleoside transporter ENT3, cause a familial histiocytosis syndrome (Faisalabad histiocytosis) and familial Rosai-Dorfman disease. PLoS Genet. 2010;6(2):e1000833.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Cliffe ST, Kramer JM, Hussain K, Robben JH, de Jong EK, de Brouwer AP, et al. SLC29A3 gene is mutated in pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome and interacts with the insulin signaling pathway. Hum Mol Genet. 2009;18(12):2257–65.

    Article  CAS  PubMed  Google Scholar 

  29. Campeau PM, Lu JT, Sule G, Jiang MM, Bae Y, Madan S, et al. Whole-exome sequencing identifies mutations in the nucleoside transporter gene SLC29A3 in dysosteosclerosis, a form of osteopetrosis. Hum Mol Genet. 2012;21(22):4904–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Molho-Pessach V, Suarez J, Perrin C, Chiaverini C, Doviner V, Tristan-Clavijo E, et al. The H syndrome: two novel mutations affecting the same amino acid residue of hENT3. J Dermatol Sci. 2010;57(1):59–61.

    Article  CAS  PubMed  Google Scholar 

  31. Spiegel R, Cliffe ST, Buckley MF, Crow YJ, Urquhart J, Horovitz Y, et al. Expanding the clinical spectrum of SLC29A3 gene defects. Eur J Med Genet. 2010;53(5):309–13.

    Article  PubMed  Google Scholar 

  32. Noavar S, Behroozi S, Tatarcheh T, Parvini F, Foroutan M, Fahimi H. A novel homozygous frame-shift mutation in the SLC29A3 gene: a new case report and review of literature. BMC Med Genet. 2019;20(1):1–7.

    Article  CAS  Google Scholar 

  33. Alkaya DU, Akpinar E, Bilguvar K, Tuysuz B. Resolution of sclerotic lesions of dysosteosclerosis due to biallelic SLC29A3 variant in a Turkish girl. Am J Med Genet A. 2021;185(7):2271–7.

    Article  Google Scholar 

  34. Besci O, Patel KA, Yıldız G, Tüfekçi O, Acinikli KY, Erbaş İM, et al. Atypical comorbidities in a child considered to have type 1 diabetes led to the diagnosis of SLC29A3 spectrum disorder. Hormones (Athens Greece). 2022;21(3):501–6.

    Article  PubMed  Google Scholar 

  35. Demir D, Aktaş Karabay E, Sözeri B, Gürsoy F, Akgün Doğan Ö, Topaktaş E, et al. H syndrome with a novel homozygous SLC29A3 mutation in two sisters. Pediatr Dermatol. 2020;37(6):1135–8.

    Article  PubMed  Google Scholar 

  36. Turan S, Mumm S, Alavanda C, Kaygusuz BS, Gurpinar Tosun B, Arman A, et al. Dysosteosclerosis: clinical and radiological evolution reflecting genetic heterogeneity. JBMR plus. 2022;6(8):e10663.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Cardis MA, Srinivasalu H, Greenberg J, Norton SA. Hyperpigmented and hypertrichotic sclerotic plaques in a child. Pediatr Dermatol. 2020;37(5):937–8.

    Article  PubMed  Google Scholar 

  38. Vural S, Ertop P, Durmaz CD, Şanlı H, Okçu Heper A, Kundakçı N, et al. Skin-dominant phenotype in a patient with H syndrome: identification of a novel mutation in the SLC29A3 gene. Cytogenet Genome Res. 2017;151(4):186–90.

    Article  CAS  PubMed  Google Scholar 

  39. Huizing M, Gahl WA. Inherited disorders of lysosomal membrane transporters. Biochim Biophys Acta Biomembr. 2020;1862(12):183336.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references


We are grateful to the patient and her family members, and everyone who participated. We also thank Human Genetic department of Golestan University of Medical Sciences for their support.


This study was financially supported by Golestan University of Medical Sciences under grant number 112526.

Author information

Authors and Affiliations



N.R., and N.MS. participated in the design of the study, revising the article and final approval of the version to be published. A.A., and N.G. contributed to the design of the work, analyzed the data, prepared figures and Tables, and revising the article. A.G., M.R., and SH.V. contributed to interpretation of data, and revising it critically for important intellectual content, and revising the article. All of the authors read and approved the final manuscript.

Corresponding authors

Correspondence to Nader Mansour Samaei or Abolfazl Amini.

Ethics declarations

Ethics approval and consent to participate

Our research was conducted according to the guidelines set forth by the Ethics Committee of Golestan University of Medical Sciences (Ethics Code: IR.GOUMS.REC.1401.227). Informed consent to participate in the study was acquired after providing the patient’s parents with written information and obtaining their informed agreement.

Consent for publication

We confirm that the parents of the patients signed written informed consent for publication of their own and their child’s genetic data, and clinical details.

Conflict of interest

The authors confirm that there are no conflicts of interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rezaie, N., Mansour Samaei, N., Ghorbani, A. et al. A novel start-loss mutation of the SLC29A3 gene in a consanguineous family with H syndrome: clinical characteristics, in silico analysis and literature review. BMC Med Genomics 17, 178 (2024).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: